Ra Capital Management, L.P. Buys 479,039 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 479,039 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49. Following the transaction, the director directly owned 15,683,034 shares in the company, valued at $108,369,764.94. This trade represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.00 per share, with a total value of $721.00.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Up 6.7%

Shares of ARTV stock opened at $8.54 on Friday. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $14.53. The stock has a market capitalization of $211.11 million, a PE ratio of -2.41 and a beta of 2.38. The firm has a 50 day moving average of $8.93 and a two-hundred day moving average of $6.14.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARTV. Citadel Advisors LLC raised its holdings in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth $341,000. Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics during the 2nd quarter worth $67,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth $112,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ARTV. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Wedbush raised their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. HC Wainwright raised their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.